Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
PaperCitations, authors & open-access status
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 412 citations, 2015 year and closed oa status.
412
Citations
2015
Year
closed
OA Status